Publications by authors named "Erick De La Torre Tarazona"
CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months.
View Article and Find Full Text PDFArticle Synopsis
- Maraviroc (MVC) is an antiretroviral drug that blocks HIV from entering cells by binding to CCR5 receptors and is being investigated as a latency reversal agent for HIV cure strategies.
- In a study, CD4 T cells were exposed to MVC to assess its impact on cell activation and metabolic rates, using techniques like flow cytometry and a Seahorse Analyzer.
- Findings showed that high concentrations of MVC did not significantly alter activation markers or metabolic rates in CD4 T cells, suggesting that MVC has a favorable safety profile as a candidate for HIV treatment without affecting immune cell functionality.
The presence of neutralizing antibodies (NAbs) is a major correlate of protection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Thus, different in vitro pseudoviruses-based assays have been described to detect NAbs against SARS-CoV-2. However, the determination of NAbs against SARS-CoV-2 in people living with HIV (PLWH) through HIV-based pseudoparticles could be influenced by cross-neutralization activity or treatment, impeding accurate titration of NAbs.
View Article and Find Full Text PDFThis article reviews the main discoveries achieved by transcriptomic approaches on HIV controller (HIC) and long-term non-progressor (LTNP) individuals, who are able to suppress HIV replication and maintain high CD4+ T cell levels, respectively, in the absence of antiretroviral therapy. Different studies using high throughput techniques have elucidated multifactorial causes implied in natural control of HIV infection. Genes related to IFN response, calcium metabolism, ribosome biogenesis, among others, are commonly differentially expressed in LTNP/HIC individuals.
View Article and Find Full Text PDFImmunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study.
EClinicalMedicine
August 2022
Article Synopsis
- The CombiVacS study examined the effectiveness and safety of combining two COVID-19 vaccines, ChAdOx1-S and BNT162b2, with initial results showing a robust immune response after 14 days.
- A secondary analysis tracked the immune response in 664 adults from the initial study up to 180 days, measuring both humoral (antibody levels) and cellular (T-cell response) immunity.
- By day 180, antibody levels declined significantly in both the intervention and control groups, indicating waning immunity over time, with notably lower responses to different COVID-19 variants.